Company news
Celularity Inc. news in 2025
Celularity Inc.'s news releases, calls and decks from 2025, newest first.
Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations
December 26, 2025
Celularity Announces Closing of Financing Transactions
December 22, 2025
Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision
December 18, 2025
Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care
October 30, 2025
Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease
October 14, 2025
Celularity Announces Filing of Form 10-Q Quarterly Reports for the First Quarter and the Second Quarter 2025, Confirmation of Nasdaq Listing Rule 5250(c)(1) Compliance
September 3, 2025
Celularity Receives Nasdaq Notice Regarding Form 10-Q
August 22, 2025
Celularity Completes Major Balance Sheet Restructuring, Retires All $41.6 Million in Senior Secured Debt
August 18, 2025
Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law
July 9, 2025
Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies
July 1, 2025
Celularity Announces Chief Financial Officer Transition
June 10, 2025
Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology
June 2, 2025
Celularity Announces Full Year 2024 Operating and Financial Results
May 9, 2025
Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees
April 25, 2025
Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products
April 14, 2025
Celularity Announces Publication of “Senescence, NK cells, and cancer: navigating the crossroads of aging and disease” in the April 4, 2025, Issue of Frontiers in Immunology
April 7, 2025
Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products
February 25, 2025
Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company
February 24, 2025
Decks in 2025
- Investor Presentation (February 2025)
Investor deck · 28 slides · February 2025